New Delhi, January 20, 2025.
Commonly used diabetes drugs could lower the risk of cardiometabolic conditions but heighten the risk of gastrointestinal and arthritic ones, hypotension, among others, according to a study.
Researchers from Washington University in St. Louis analysed data from the US Department of Veterans Affairs to examine links between taking ‘GLP-1RA’ drugs and 175 health outcomes. Data from 2.4 million participants with diabetes were analysed.
GLP-1RA, or glucagon-like peptide 1 receptor agonists, are drugs that work by mimicking the action of the hormone GLP-1 that helps control blood sugar and promote feelings of satiety. Through weight management, the drugs can also treat type 2 diabetes.
